
James S. Bergin
Examiner (ID: 16751)
| Most Active Art Unit | 3641 |
| Art Unit(s) | 2164, 3641, 3643, 3616, 3624 |
| Total Applications | 1858 |
| Issued Applications | 1409 |
| Pending Applications | 166 |
| Abandoned Applications | 313 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17385581
[patent_doc_number] => 20220033433
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS
[patent_app_type] => utility
[patent_app_number] => 17/323367
[patent_app_country] => US
[patent_app_date] => 2021-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9398
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17323367
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/323367 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | May 17, 2021 | Abandoned |
Array
(
[id] => 18854137
[patent_doc_number] => 11851700
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-12-26
[patent_title] => Methods, kits, and compositions for processing extracellular molecules
[patent_app_type] => utility
[patent_app_number] => 17/318364
[patent_app_country] => US
[patent_app_date] => 2021-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 21
[patent_no_of_words] => 54369
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17318364
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/318364 | Methods, kits, and compositions for processing extracellular molecules | May 11, 2021 | Issued |
Array
(
[id] => 18737927
[patent_doc_number] => 20230346829
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/998644
[patent_app_country] => US
[patent_app_date] => 2021-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29790
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998644
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/998644 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | May 10, 2021 | Abandoned |
Array
(
[id] => 18664848
[patent_doc_number] => 11771713
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-03
[patent_title] => Betalain compositions and methods therefor
[patent_app_type] => utility
[patent_app_number] => 17/313982
[patent_app_country] => US
[patent_app_date] => 2021-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9181
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 147
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313982
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/313982 | Betalain compositions and methods therefor | May 5, 2021 | Issued |
Array
(
[id] => 18871167
[patent_doc_number] => 11858953
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-02
[patent_title] => Compositions and methods for synthesis of phosphorylated molecules
[patent_app_type] => utility
[patent_app_number] => 17/307567
[patent_app_country] => US
[patent_app_date] => 2021-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 140
[patent_figures_cnt] => 144
[patent_no_of_words] => 25843
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17307567
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/307567 | Compositions and methods for synthesis of phosphorylated molecules | May 3, 2021 | Issued |
Array
(
[id] => 17243425
[patent_doc_number] => 20210363168
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/246090
[patent_app_country] => US
[patent_app_date] => 2021-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 144118
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17246090
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/246090 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | Apr 29, 2021 | Issued |
Array
(
[id] => 17035076
[patent_doc_number] => 20210252034
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => DEOXYRIBONUCLEOSIDE MONOPHOSPATE BYPASS THERAPY FOR MITOCHONDRIAL DNA DEPLETION SYNDROME
[patent_app_type] => utility
[patent_app_number] => 17/242862
[patent_app_country] => US
[patent_app_date] => 2021-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12650
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17242862
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/242862 | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome | Apr 27, 2021 | Issued |
Array
(
[id] => 17020884
[patent_doc_number] => 20210244755
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => METHODS FOR TREATING CANCERS BY PRODRUGS OF CLOFARABINE
[patent_app_type] => utility
[patent_app_number] => 17/241087
[patent_app_country] => US
[patent_app_date] => 2021-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9833
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17241087
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/241087 | Methods for treating cancers by prodrugs of clofarabine | Apr 26, 2021 | Issued |
Array
(
[id] => 17290933
[patent_doc_number] => 20210386772
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => CHEMOTHERAPY DRUG-SENSITIZING METHOD, AGENT COMPOSITION AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/239318
[patent_app_country] => US
[patent_app_date] => 2021-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3953
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17239318
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/239318 | Chemotherapy drug-sensitizing method, agent composition and use thereof | Apr 22, 2021 | Issued |
Array
(
[id] => 17183804
[patent_doc_number] => 20210330689
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => COMPOSITION FOR TREATING BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/238182
[patent_app_country] => US
[patent_app_date] => 2021-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12206
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17238182
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/238182 | Composition for treating blood cancer using 4'-thio-5-Aza-2'-deoxycytidine and uses thereof | Apr 21, 2021 | Issued |
Array
(
[id] => 18497369
[patent_doc_number] => 20230219993
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG
[patent_app_type] => utility
[patent_app_number] => 17/996430
[patent_app_country] => US
[patent_app_date] => 2021-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28329
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996430
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/996430 | Antiviral application of nucleoside analog or combination formulation containing nucleoside analog | Apr 15, 2021 | Issued |
Array
(
[id] => 17383876
[patent_doc_number] => 20220031728
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => FORMULATIONS OF PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE DRUGS
[patent_app_type] => utility
[patent_app_number] => 17/231606
[patent_app_country] => US
[patent_app_date] => 2021-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10429
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17231606
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/231606 | Formulations of phosphoramidate derivatives of nucleoside drugs | Apr 14, 2021 | Issued |
Array
(
[id] => 18626637
[patent_doc_number] => 20230285434
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => METHOD FOR TREATING ARENAVIRIDAE INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/918964
[patent_app_country] => US
[patent_app_date] => 2021-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13950
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918964
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/918964 | METHOD FOR TREATING ARENAVIRIDAE INFECTIONS | Apr 13, 2021 | Abandoned |
Array
(
[id] => 18673017
[patent_doc_number] => 20230310481
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E
[patent_app_type] => utility
[patent_app_number] => 17/996083
[patent_app_country] => US
[patent_app_date] => 2021-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19125
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996083
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/996083 | BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | Apr 12, 2021 | Pending |
Array
(
[id] => 17156387
[patent_doc_number] => 20210317438
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => Isolation of Nucleic Acids from Environmental Samples Using Magnetic Particles
[patent_app_type] => utility
[patent_app_number] => 17/225263
[patent_app_country] => US
[patent_app_date] => 2021-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5803
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17225263
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/225263 | Isolation of nucleic acids from environmental samples using magnetic particles | Apr 7, 2021 | Issued |
Array
(
[id] => 20356218
[patent_doc_number] => 12472197
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-18
[patent_title] => Methods, compositions, and dosing regimens for treatment of SARS-CoV-2 infections
[patent_app_type] => utility
[patent_app_number] => 17/995793
[patent_app_country] => US
[patent_app_date] => 2021-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 8
[patent_no_of_words] => 19031
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995793
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/995793 | Methods, compositions, and dosing regimens for treatment of SARS-CoV-2 infections | Apr 6, 2021 | Issued |
Array
(
[id] => 17243428
[patent_doc_number] => 20210363171
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/222515
[patent_app_country] => US
[patent_app_date] => 2021-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51544
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17222515
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/222515 | Methods of synthesizing substituted purine compounds | Apr 4, 2021 | Issued |
Array
(
[id] => 18466969
[patent_doc_number] => 20230201249
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => COMPOSITIONS INCORPORATING SULFATED POLYSACCHARIDES FOR INHIBITING SARS-COV-2
[patent_app_type] => utility
[patent_app_number] => 17/915783
[patent_app_country] => US
[patent_app_date] => 2021-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4841
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17915783
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/915783 | COMPOSITIONS INCORPORATING SULFATED POLYSACCHARIDES FOR INHIBITING SARS-COV-2 | Apr 1, 2021 | Abandoned |
Array
(
[id] => 20525978
[patent_doc_number] => 12544397
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-02-10
[patent_title] => Compositions and methods containing N-acetylcystein and nicotinamide riboside for prevention and treatment of neurological diseases and conditions
[patent_app_type] => utility
[patent_app_number] => 17/907160
[patent_app_country] => US
[patent_app_date] => 2021-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 3271
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907160
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/907160 | Compositions and methods containing N-acetylcystein and nicotinamide riboside for prevention and treatment of neurological diseases and conditions | Mar 31, 2021 | Issued |
Array
(
[id] => 18762892
[patent_doc_number] => 11813271
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-14
[patent_title] => Sialic acid compositions for the use of inhibiting and treating coronavirus infection
[patent_app_type] => utility
[patent_app_number] => 17/916104
[patent_app_country] => US
[patent_app_date] => 2021-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 7960
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916104
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/916104 | Sialic acid compositions for the use of inhibiting and treating coronavirus infection | Mar 30, 2021 | Issued |